Pangaea Oncology S.A. Cash Flow Conversion Efficiency
Pangaea Oncology S.A. cash flow conversion efficiency. Based on the latest financial reports, Pangaea Oncology S.A. (PANG) has a cash flow conversion efficiency ratio of -0.057x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.25 Million ≈ $-1.47 Million USD) by net assets (€22.06 Million ≈ $25.79 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Pangaea Oncology S.A. (2013–2025)
Cash flow conversion efficiency of Pangaea Oncology S.A. from 2013 to 2025. This chart illustrates how Pangaea Oncology S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View Pangaea Oncology S.A. stock quote for real-time trading data and today's change.
Pangaea Oncology S.A. Cash Flow Conversion Ratio Explained
Pangaea Oncology S.A. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Pangaea Oncology S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pangaea Oncology S.A. ranked by their cash flow conversion efficiency. Also see market value of Pangaea Oncology S.A. for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Marketwise Inc
NASDAQ:MKTW
|
-0.084x |
|
DDC Enterprise Limited
NYSE MKT:DDC
|
-0.021x |
|
International Conveyors Limited
NSE:INTLCONV
|
-0.015x |
|
flyExclusive, Inc.
NYSE:FLYX
|
-0.007x |
|
Pirate Gold Corp.
V:YARR
|
-0.259x |
|
DYO Boya Fabrikalari Sanayi ve Ticaret AS
IS:DYOBY
|
0.068x |
|
Muda Holdings Bhd
KLSE:3883
|
0.000x |
|
ktcs corporation
KO:058850
|
-0.054x |
Annual Cash Flow Conversion Efficiency for Pangaea Oncology S.A. (2013–2025)
The table below shows the annual cash flow conversion efficiency of Pangaea Oncology S.A. from 2013 to 2025. Review Pangaea Oncology S.A. leverage flexibility ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €22.06 Million ≈ $25.79 Million |
€-2.52 Million ≈ $-2.95 Million |
-0.114x | +42.85% |
| 2024-12-31 | €22.84 Million ≈ $26.70 Million |
€-4.57 Million ≈ $-5.34 Million |
-0.200x | -56.82% |
| 2023-12-31 | €18.81 Million ≈ $21.99 Million |
€-2.40 Million ≈ $-2.80 Million |
-0.127x | +19.97% |
| 2022-12-31 | €23.08 Million ≈ $26.98 Million |
€-3.68 Million ≈ $-4.30 Million |
-0.159x | +10.27% |
| 2021-12-31 | €14.09 Million ≈ $16.47 Million |
€-2.50 Million ≈ $-2.92 Million |
-0.178x | +20.60% |
| 2020-12-31 | €8.57 Million ≈ $10.01 Million |
€-1.92 Million ≈ $-2.24 Million |
-0.224x | +22.45% |
| 2019-12-31 | €8.31 Million ≈ $9.72 Million |
€-2.40 Million ≈ $-2.80 Million |
-0.288x | -14.68% |
| 2018-12-31 | €8.62 Million ≈ $10.07 Million |
€-2.17 Million ≈ $-2.53 Million |
-0.251x | +80.42% |
| 2017-12-31 | €5.05 Million ≈ $5.90 Million |
€-6.48 Million ≈ $-7.58 Million |
-1.284x | -336.22% |
| 2016-12-31 | €6.05 Million ≈ $7.07 Million |
€-1.78 Million ≈ $-2.08 Million |
-0.294x | +86.59% |
| 2015-12-31 | €1.05 Million ≈ $1.23 Million |
€-2.31 Million ≈ $-2.70 Million |
-2.194x | -88.79% |
| 2014-12-31 | €1.63 Million ≈ $1.90 Million |
€-1.89 Million ≈ $-2.21 Million |
-1.162x | -221.80% |
| 2013-12-31 | €1.83 Million ≈ $2.14 Million |
€-659.69K ≈ $-771.25K |
-0.361x | -- |
About Pangaea Oncology S.A.
Pangaea Oncology, S.A., a precision oncology company, provides a range of services to cancer patients in Spain and the rest of European Union countries. The company offers molecular diagnostics, including mutation analysis in tissue and liquid biopsy; gene amplification and translocation testing; immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH); gene expression profiling a… Read more